Academic Journal
Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections
| العنوان: | Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections |
|---|---|
| المؤلفون: | Zoe A. Stewart, MD, PhD, Jeffrey Stern, MD, Nicole M. Ali, MD, Harmit S. Kalia, DO, Karen Khalil, PharmD, Srijana Jonchhe, PharmD, Elaina P. Weldon, MSN, Rebecca A. Dieter, PharmD, Tyler C. Lewis, PharmD, Nur Funches, BS, Sudara Crosby, AA, Monique Seow, HSD, Jonathan C. Berger, MD, Nabil N. Dagher, MD, Bruce E. Gelb, MD, Anthony C. Watkins, MD, Nader Moazami, MD, Deane E. Smith, MD, Zachary N. Kon, MD, Stephanie H. Chang, MD, Alex Reyentovich, MD, Luis F. Angel, MD, Robert A. Montgomery, MD, PhD, Bonnie E. Lonze, MD, PhD |
| المصدر: | Transplantation Direct, Vol 7, Iss 10, p e762 (2021) |
| بيانات النشر: | Wolters Kluwer, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Surgery |
| مصطلحات موضوعية: | Surgery, RD1-811 |
| الوصف: | Background. Transplanting hepatitis C viremic donor organs into hepatitis C virus (HCV)-negative recipients is becoming increasingly common; however, practices for posttransplant direct-acting antiviral (DAA) treatment vary widely. Protracted insurance authorization processes for DAA therapy often lead to treatment delays. Methods. At our institution, 2 strategies for providing DAA therapy to HCV– recipients of HCV+ transplants have been used. For thoracic organ recipients, an institution-subsidized course of initial therapy was provided to ensure an early treatment initiation date. For abdominal organ recipients, insurance approval for DAA coverage was sought once viremia developed, and treatment was initiated only once the insurance-authorized supply of drug was received. To evaluate the clinical impact of these 2 strategies, we retrospectively collected data pertaining to the timing of DAA initiation, duration of recipient viremia, and monetary costs incurred by patients and the institution for patients managed under these 2 DAA coverage strategies. Results. One hundred fifty-two transplants were performed using HCV viremic donor organs. Eighty-nine patients received DAA treatment without subsidy, and 62 received DAA treatment with subsidy. One patient who never developed viremia posttransplant received no treatment. Subsidizing the initial course enabled earlier treatment initiation (median, 4 d [interquartile range (IQR), 2–7] vs 10 [IQR, 8–13]; P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2373-8731 00000000 |
| Relation: | http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001222; https://doaj.org/toc/2373-8731 |
| DOI: | 10.1097/TXD.0000000000001222 |
| URL الوصول: | https://doaj.org/article/99c75af3fbae48519e245fd9aae43cb9 |
| رقم الانضمام: | edsdoj.99c75af3fbae48519e245fd9aae43cb9 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23738731 00000000 |
|---|---|
| DOI: | 10.1097/TXD.0000000000001222 |